Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478311 | 0.84 | FABP5 (0.36) | CA1CA2MMP2MMP9MMP12 | |
| SCHEMBL4606085 | 0.82 | TSHR (0.32) | CA1CA2MMP2MMP9MMP12 | |
| SCHEMBL1935691 | 0.81 | CA1 (0.36) | CA1CA2MMP2MMP9MMP12 | |
| SCHEMBL7714728 | 0.68 | TSHR (0.39) | CA1CA2TSHR | |
| SCHEMBL5140755 | 0.67 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL29430507 | 0.66 | FABP5 (0.48) | CA1CA2TSHR | |
| SCHEMBL789074 | 0.66 | FABP5 (0.48) | CA1CA2TSHR | |
| SCHEMBL4605373 | 0.65 | TSHR (0.40) | CA1CA2TSHR | |
| SCHEMBL3491073 | 0.65 | FABP5 (0.39) | CA1CA2TSHR | |
| SCHEMBL4606087 | 0.65 | HRH3 (0.32) | CA1CA2MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937040-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8906866-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140073559-A1 | Antibiotic Compositions for the Treatment of Gram Negative Infections | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130345121-A1 | Antibiotic Compositions For The Treatment of Gram Negative Infections | BIOSOURCE PHARM, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8415307-B1 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8343912-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2010075416-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | BIOSOURCE PHARM, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | BIOSOURCE PHARM, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345121-A1 | Antibiotic Compositions For The Treatment of Gram Negative Infections | PSMB7, MDN1, PSMB6 | CA1 4874/4885CA2 4850/4885MMP2 2365/4885 |
| US-20140073559-A1 | Antibiotic Compositions for the Treatment of Gram Negative Infections | RPN2, NRDC, RPN1 | CA1 4871/4885CA2 4776/4885MMP2 1665/4885 |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | PSMB7, IL17A, IL1B | CA1 4878/4885CA2 4856/4885MMP2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.